San Antonio Cardiovascular Proteomics Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78245, USA.
Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H919-30. doi: 10.1152/ajpheart.00577.2012. Epub 2012 Aug 17.
Since the discovery of tadpole collagenase in 1962, the matrix metalloproteinase (MMP) family has emerged as a significant proteinase group with recognized effects on the cardiovascular system. Over the last 40 years, many milestones have been achieved, from the identification of the first MMP, to the generation of the first MMP cDNA clone and null mouse, to the clinical approval of the first MMP inhibitor. Over the years, a few myths and misunderstandings have interwoven into the truths. In this review, we will discuss the major milestones of MMP research, as well as review the misinterpretations and misperceptions that have evolved. Clarifying the confusions and dispelling the myths will both provide a better understanding of MMP properties and functions and focus the cardiovascular field on the outstanding research questions that need to be addressed.
自 1962 年发现蝌蚪胶原酶以来,基质金属蛋白酶(MMP)家族已成为一个重要的蛋白酶家族,其对心血管系统的影响已得到公认。在过去的 40 年中,已经取得了许多里程碑式的成就,从鉴定第一种 MMP 到生成第一种 MMP cDNA 克隆和缺失小鼠,再到第一种 MMP 抑制剂的临床批准。多年来,一些神话和误解交织在一起。在这篇综述中,我们将讨论 MMP 研究的主要里程碑,并回顾由此产生的误解和误解。澄清这些混淆,消除这些神话,将有助于更好地理解 MMP 的性质和功能,并使心血管领域专注于需要解决的突出研究问题。